Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CTIM-76
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Context Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Lonza will support the development and manufacturing of CTIM-76, a CLDN6 x CD3 bispecific antibody clinical candidate. The bispecific antibody-based therapy is being developed to redirect T-cell mediated lysis toward malignant cells ...
Brand Name : CTIM-76
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 09, 2023
Lead Product(s) : CTIM-76
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Context Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
